BioCardia, Inc. Share Price
NASDAQ: BCDA | Micro CapBioCardia, Inc. Stock Performance
BioCardia, Inc. Share Price Chart
BioCardia, Inc. Quarterly Profit & Loss
All figures in USD
BioCardia, Inc. Annual Profit & Loss
All figures in USD
About BioCardia, Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
BioCardia, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Oct 2026 | $1.03 | $0.93 | -10.53% |
Sep 2026 | $1.11 | $1.03 | -12.29% |
Aug 2026 | $0.85 | $1.18 | +46.40% |
Jul 2026 | $1.21 | $0.81 | -35.52% |
Jun 2026 | $0.90 | $1.25 | +35.72% |
May 2026 | $1.13 | $0.92 | -19.91% |
Apr 2026 | $1.17 | $1.15 | -1.29% |
Mar 2026 | $1.35 | $1.17 | -10.73% |
Feb 2026 | $1.12 | $1.30 | +6.10% |
Jan 2026 | $1.26 | $1.23 | -1.60% |
Dec 2025 | $1.42 | $1.25 | -12.89% |
Nov 2025 | $1.41 | $1.44 | +3.24% |